Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,578
  • Shares Outstanding, K 14,289
  • Annual Sales, $ 10 K
  • Annual Income, $ -4,050 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.78
  • Price/Sales -2,957.80
  • Price/Cash Flow N/A
  • Price/Book 9.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.38
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +51.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +15.26%
on 12/09/25
2.54 -18.50%
on 12/15/25
+0.23 (+12.50%)
since 12/08/25
3-Month
1.61 +28.57%
on 11/21/25
2.54 -18.50%
on 12/15/25
-0.22 (-9.61%)
since 10/08/25
52-Week
1.61 +28.57%
on 11/21/25
9.19 -77.48%
on 07/14/25
-1.18 (-36.31%)
since 01/08/25

Most Recent Stories

More News
Biotech’s New Edge: 5 Companies Mastering "How" We Dose

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. VANCOUVER – Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by 2034 as industry...

MOOD.CN : 0.6000 (-14.29%)
WST : 275.23 (-1.15%)
PODD : 292.89 (-2.10%)
DOSEF : 0.5675 (+18.80%)
LPCN : 7.53 (+0.13%)
DARE : 2.07 (+5.08%)
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital...

DARE : 2.07 (+5.08%)
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) --  Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 2.07 (+5.08%)
Daré Bioscience Receives $3.6 Million in Additional Grant Funding

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 2.07 (+5.08%)
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports...

DARE : 2.07 (+5.08%)
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science...

DARE : 2.07 (+5.08%)
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 2.07 (+5.08%)
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...

DARE : 2.07 (+5.08%)
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and...

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real...

DARE : 2.07 (+5.08%)
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and...

DARE : 2.07 (+5.08%)

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 2.20
2nd Resistance Point 2.14
1st Resistance Point 2.10
Last Price 2.07
1st Support Level 2.00
2nd Support Level 1.94
3rd Support Level 1.90

See More

52-Week High 9.19
Fibonacci 61.8% 6.29
Fibonacci 50% 5.40
Fibonacci 38.2% 4.51
Last Price 2.07
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar